Portal de Periódicos da CAPES

Pharmacology and Clinical Use of the New ACE‐Inhibitor Moexipril

1995; Wiley; Volume: 13; Issue: 3 Linguagem: Inglês

10.1111/j.1527-3466.1995.tb00304.x

1527-3466

Michael Stimpel, Rainer Bonn, Brigitte Koch, Kenneth Dickstein,

Pharmaceutical studies and practices

Cardiovascular Drug ReviewsVolume 13, Issue 3 p. 211-229 Free to Read Pharmacology and Clinical Use of the New ACE-Inhibitor Moexipril Michael Stimpel, Corresponding Author Michael Stimpel Departments of Cardiovascular Clinical Research, Schwarz Pharma AG, Monheim am Rhein, Germany.Address correspondence and reprint requests to Dr. Michael Stimpel, at the Department of Cardiovascular Clinical Research, Schwarz Pharma AG, Alfred-Nobel-Str. 10, D-40789 Monheim am Rhein, GermanySearch for more papers by this authorRainer Bonn, Rainer Bonn Departments of Human Pharmacology, Schwarz Pharma AG, Monheim am Rhein, Germany.Search for more papers by this authorBrigitte Koch, Brigitte Koch Departments of Cardiovascular Clinical Research, Schwarz Pharma AG, Monheim am Rhein, Germany.Search for more papers by this authorKenneth Dickstein, Kenneth Dickstein Departments of Cardiology Division, Central Hospital, Rogaland, Stavanger, NorwaySearch for more papers by this author Michael Stimpel, Corresponding Author Michael Stimpel Departments of Cardiovascular Clinical Research, Schwarz Pharma AG, Monheim am Rhein, Germany.Address correspondence and reprint requests to Dr. Michael Stimpel, at the Department of Cardiovascular Clinical Research, Schwarz Pharma AG, Alfred-Nobel-Str. 10, D-40789 Monheim am Rhein, GermanySearch for more papers by this authorRainer Bonn, Rainer Bonn Departments of Human Pharmacology, Schwarz Pharma AG, Monheim am Rhein, Germany.Search for more papers by this authorBrigitte Koch, Brigitte Koch Departments of Cardiovascular Clinical Research, Schwarz Pharma AG, Monheim am Rhein, Germany.Search for more papers by this authorKenneth Dickstein, Kenneth Dickstein Departments of Cardiology Division, Central Hospital, Rogaland, Stavanger, NorwaySearch for more papers by this author First published: September 1995 https://doi.org/10.1111/j.1527-3466.1995.tb00304.xCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Abernathy DR, Fox AAL, Stimpel M. Moexipril in the treatment of mild to moderate essential hypertension: Comparison with sustained release verapamil. J Clin Pharmacol 1995; 35: 794–799. 2 Bafour JA, Goa KL. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs 1991; 42: 511–539. 3 Brunner HR, Waeber B, Nussberger J. Angiotensin-converting enzyme inhibitors in arterial hypertension. In FH Messerli (ed). Cardiovascular Drug Therapy, 2nd edition. Philadelphia : WB Saunders, 1995, in press. 4 Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1–5. 5 Chrysant SG, Fox AAL, Stimpel M. Comparison of moexipril—a novel ACE-inhibitor—to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. Am J Hypertension 1995; 8: 418–421. 6 Dickstein K, Aarsland T, Ferrari P, Todd M, Stimpel M. Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. J Cardiovasc Pharmacol 1994; 24: 247–255. 7 Drayer JI, Stimpel M, Fox AAL, Weber MA. The antihypertensive properties of the angiotensin converting enzyme inhibitor moexipril given alone or in combination with a low dose of a diuretic. Am J Therap 1995; 2: 525–531. 8 Edling O, Gohlke P, Bao G, Unger Th. In vitro und in vivo Charakterisierung des neuen ACE-hemmers Moexipril: Vergleich mit Enalapril. Hochdruck 1993; 12: 49. 9 Edling O, Bao G, Feelisch M, Unger T, Gohlke P. Characterization of the new ACE inhibitor moexipril. J Pharmacol Exp Ther 1995; submitted. 10 Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62: 749–756. 11 Girard M. The safety of angiotensin-converting enzyme (ACE) inhibitors in moderate hypertension. Adverse Drug React Toxicol Rev 1991; 10: 169–185. 12 Grass GM, Morehead W. Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res 1989; 6: 759–765. 13 Gu L, Strickley RG. Diketopiperazine formation, hydrolysis epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085. Pharm Res 1987; 4: 392–397. 14 Heel RC, Brogden RN, Speight TM, Avery GS: Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 1980; 20: 409–452. 15 Hoefle ML, Klutchko S. Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids. US Pat. 1982;4.344.949. 16 Hui KK, Duchin KL, Kripalani KJ, Chan D, Kramer PK, Yanagawa N. Pharmacokinetics of fosinopril in patients with various degrees of renal function. Clin Pharmacol Ther 1991; 49: 457–467. 17 Hutt V, Strobl W, Pabst G. Evaluation of dose linearity of moexipril. Submitted for publication. 18 Hutt V, Michaelis K, Verbesselt R. Lack of pharmacokinetic or clinically pharmacodynamic interactions between moexipril and hydrochlorothiazide. Europ J Pharmacol 1996;in press. 19 Klutchko S, Blankley CJ, Fleming RW, et al. Synthesis of the novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationship for non-sulfhydryl and sulfhydryl types. J Med Chem 1986; 29: 1953–1961. 20 Koch B, Stimpel M, Andersson O. Low-dose combinations of moexipril and hydrochlorothiazide in the treatment of hypertension. Pharmacol Res 1995; 31(suppl.): 328. 21 Koch B, Stimpel M. Do hypertensive women respond differently to low dosages of moexipril and hydrochlorothiazide Hypertension 1995; 26: 1383. 22 Lancaster SG, Todd PA. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646–669. 23 Lucas CP, Darga LL, Fox AAL, Stimpel M. A study of the efficacy and safety of moexipril in mild to moderate hypertension. Am J Therap 1995; in press. 24 Mac Fayden RJ, Lees Kr, Reid JL. Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol 1991; 31: 1–5. 25 Massarella IW, DeFeo TM, Brown AN, Lin A, Wills RI. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril. Br J Clin Pharmacol 1989; 27: 205 S–209 S. 26 Parish RC, Miller LJ. Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update. Drug Safety 1992; 7: 14–31. 27 Persson B, Fox AAL, Stimpel M. Evaluation of the antihypertensive efficacy and tolerability of moexipril, a new ACE inhibitor, compared to hydrochlorothiazide in elderly patients. Europ J Clin Pharmacol, in press. 28 Persson B, Widgren BR, Fox AAL, Stimpel M. Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension. J Cardiovasc Pharmacol 1995; 26: 73–78. 29 Saunders E, Weir MR, Kong W, Hollifield J, Gray J, et al. A comparison of the efficacy and safety of a alpha-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707–1713. 30 Schini BV, Boulanger C, Regoli D, Vanhoutte PM. Bradykinin stimulates the production of cyclic GMP via activation of B2-kinin receptors in cultured porcine aortic endothelial cells. J Pharmacol Exp Ther 1990; 252: 581–586. 31 Singhvi SM, Duchin KL, Morrision RA, Willard DA, Everett DW, Frantz M. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 1988; 25: 9–15. 32 Stimpel M, Cawello W. Pharmacokinetics and ACE-inhibition of the new ACE-inhibitor moexipril: Is coadministration with food of clinical relevance Hypertension 1995; 26: 1384. 33 Stimpel M, Koch B, Dickstein K. Moexipril as add-on therapy to hydrochlorothiazide in moderate to severe hypertension. Pharmacol Res 1995; 31(suppl.): 329. 34 Stimpel M, Koch B, Persson B. Treatment of hypertension in elderly patients: Comparison of moexipril to hydrochlorothiazide. Pharmacol Res 1995; 31(suppl.): 328. 35 Stimpel M, Loh IK. Moexipril versus captopril in patients with mild to moderate hypertension. Am J Hypertension 1995; 8: 183A. 36 Swales JD. The renin-angiontensin system as a target for therapeutic intervention. J Cardiovasc Pharmacol 1994; 24(suppl. 2): 91–95. 37 The CONSENSUS Study Trial Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the North Scandinavian enalapril survival study (CONSENSUS). N Engl J Med 1987; 316: 1429–1435. 38 The SOLVD Investigators. Effect of enalapril on survival in patients with reduced ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293–302. 39 Todd PA, Benfield P. Ramipril: A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders. Drugs 1990; 39: 110–135. 40 Todd PA, Fitton A. Perindopril: A review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991; 42: 90–114. 41 Todd PA, Heel RC. Enalapril: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198–248. 42 Van Hecken A, Verbesselt R, Depre M, et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol 1993; 45: 291–293. 43 Veltmar A, Gohlke P, Unger T. From tissue angiotensin converting enzyme inhibition to antihypertensive effect. Am J Hypertension 1991; 4: 263S–269S. 44 Waldmeier F, Kaiser G, Ackermann R, et al. The disposition of [14C]-labelled benazepril HC1 in normal adult volunteers after single and repeated oral dose. Xenobiotica 1991; 21: 251–261. 45 Waeber B, Juillart-Jeanneret L, Aubert JF, Schapira M, Nussberger J, Brunner HR. Involvement of the kallikrein-kinin system in the antihypertensive effect of the angiotensin enzyme inhibitors. Br Clin Pharmacol 1989; 27: 175S. 46 White WB, Fox AAL, Stimpel M. Long-term efficacy and safety of moexipril in the treatment of hypertension. J Hum Hypertension 1994; 8: 917–921. 47 White WB, Stimpel M. Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension. J Hum Hypertension 1995; in press. 48 White WB, Whelton A, Fox AAL, Stimpel M, Kaihlanen PM. Tri-center assessment of the efficacy and pharmacodynamics of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. J Clin Pharmacol 1995; 35: 233–238. Citing Literature Volume13, Issue3September 1995Pages 211-229 ReferencesRelatedInformation